Fresh analysis suggests that people who discontinue popular GLP-1 drugs like Mounjaro or Wegovy can put back on reduced body mass far faster than those who end traditional diet and exercise regimens.
Published data in a prominent health publication points out that while overweight individuals can lose a large proportion of their body weight while on the medication, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"People buying such treatments should be aware of the potential of rapid weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight within about a year and a half.
Comparing Therapies
The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the results of these new drugs with conventional dieting.
Scientists point out that individuals who shed pounds through dieting typically experience a more gradual weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Fast Rebound
Experts believe the mode of action of the drugs explains the heightened rebound.
These medications mimic a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the body to produce less of its own natural GLP-1, and could diminish sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means hunger is uncontrolled, making binge eating much more probable."
A Chronic Disease?
Health authorities recommend the jabs for people with obesity-related health risks, alongside recommended lifestyle changes.
A number of clinicians contend that, given the likelihood of weight regain, the therapy is often long-term.
This opinion is echoed by pharmaceutical companies, who state that the findings "underscore the long-term character of excess weight," akin to managing diseases like diabetes.
User Experiences
Users who have discontinued the medication describe a intense resurgence of cravings.
"It was like something activating and I was suddenly starving," described one woman.
This difficulty is compounded if patients have not adopted permanent lifestyle or habit modifications during treatment.
Growing Interest
Recent estimates suggest that millions of people in the UK have used these injections in the past year, with interest being substantial.
- Use is higher among women compared to men.
- The 40s and 50s age group shows the greatest level of interest.
- Many obtain the drugs through private prescriptions rather than public health services.
Ultimately, experts emphasize that while these medications are potent agents for shedding pounds, they are not a standalone solution and lasting health benefits relies on combined lifestyle management.
